Purple Biotech Ltd. has released its financial results for the third quarter of 2026, showcasing its commitment to advancing its immunotherapy platform. The report, issued on November 17, 2026, also provides a business update on its lead candidate, IM1240. This update is significant as it outlines the company's future direction and the potential impact on the pharmaceutical industry.
Background
Purple Biotech Ltd. (NASDAQ/TASE: PPBT) is a biotechnology company focused on developing innovative immunotherapy solutions. The company operates under the Standard Industrial Classification of 2834, which pertains to Pharmaceutical Preparations. Recent filings include a Schedule 13G on November 12, 2026, and a Form F-3/A on November 6, 2026, among others.
What the Filing Says
According to the filing, Purple Biotech announced, "On November 17, 2026, Purple Biotech Ltd. issued a press release 'Purple Biotech Reports Third Quarter 2026 Financial Results and Provides Business Update,' which is attached hereto as Exhibit 99.1." The press release highlights the upcoming submission of an Investigational New Drug (IND) application for IM1240, with a first-in-human study planned for 2027. Additionally, data on IM1240 will be presented at the 38th EORTC-NCI-AACR Symposium on November 20, 2026.
Impact
This update from Purple Biotech may significantly affect its stakeholders, including investors, researchers, and patients with advanced solid tumors. The company's focus on innovative treatments using its CAPTN-3 platform could provide new options for patients who do not respond to existing therapies.
What's Next
The filing does not specify what happens next beyond the planned IND application submission and the upcoming presentation at the symposium.
Read Next
Adagene Launches Phase 1 Trial for Colorectal Cancer Therapy
Netlist Inc. Appoints James Hickey to Board of Directors
bioAffinity Technologies reports record CyPath® lung tests
Electra Battery Materials Expands Nickel Strategy with Positive
Boynton John Wilson IV sells shares in Nebius Group N.V.
Linkhome Holdings adds two independent directors to board









